Research graph
References from From bench to beside: luteolin's therapeutic promise in neurological disorders. Local targets link to admitted publications; unresolved targets remain external evidence.
The global burden of neurological disorders: translating evidence into policy
10.1016/s1474-4422(19)30411-9 · 2020 · External reference
Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic
10.1016/s0140-6736(21)02143-7 · 2021 · External reference
Alzheimer’s disease
10.1016/s0140-6736(20)32205-4 · 2021 · External reference
Diagnosis and treatment of Parkinson disease: a review
10.1001/jama.2019.22360 · 2020 · External reference
Neuropsychological profile linked to low dopamine: in Alzheimer’s disease, major depression, and Parkinson’s disease
10.1136/jnnp.53.10.915 · 1990 · External reference
A multi-trait association analysis of brain disorders and platelet traits identifies novel susceptibility loci for major depression, Alzheimer’s and Parkinson’s Disease
10.3390/cells12020245 · 2023 · External reference
Luteolin as a modulator of skin aging and inflammation
10.1002/biof.1699 · 2021 · External reference
Paving luteolin therapeutic potentialities and agro-food-pharma applications: emphasis on in vivo pharmacological effects and bioavailability traits
10.1155/2021/1987588 · 2021 · External reference
Protection against Alzheimer’s disease by luteolin: role of brain glucose regulation, anti-inflammatory activity, and the gut microbiota-liver-brain axis
10.1002/biof.1703 · 2021 · External reference
Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants
10.1021/jf000892m · 2001 · External reference
Flavonols and flavones as potential anti-inflammatory, antioxidant, and antibacterial compounds
10.1155/2022/9966750 · 2022 · External reference
Flavonoids and caffeoylquinic acids in Chrysanthemum morifolium Ramat flowers: a potentially rich source of bioactive compounds
10.1016/j.foodchem.2020.128733 · 2021 · External reference
Luteolin, a promising quorum quencher mitigates virulence factors production in Pseudomonas aeruginosa - in vitro and in vivo approach
10.1016/j.micpath.2023.106123 · 2023 · External reference
Bisphenol A-induced ovarian damage countered by luteolin: experiments in in vitro CHO cells and in vivo PCOS phenotype zebrafish
10.1016/j.tice.2024.102532 · 2024 · External reference
An integrated pharmacology-based analysis for antidepressant mechanism of Chinese herbal formula Xiao-Yao-San
10.3389/fphar.2020.00284 · 2020 · External reference
Luteolin ameliorates chronic stress-induced depressive-like behaviors in mice by promoting the Arginase-1+ microglial phenotype via a PPARγ-dependent mechanism
10.1038/s41401-024-01402-9 · 2025 · External reference
Luteolin as an anti-inflammatory and neuroprotective agent: a brief review
10.1016/j.brainresbull.2015.09.002 · 2015 · External reference
Luteolin for neurodegenerative diseases: a review
10.1007/s43440-024-00610-8 · 2024 · External reference
Therapeutic potential of luteolin in neurodegenerative disorders: targeting Nrf2, NF-κB, MAPK, and JAK-STAT pathways to combat neuroinflammation and apoptosis
10.1007/s10787-025-01846-3 · 2025 · External reference
Genetic evidence supporting a causal role of depression in Alzheimer's disease
10.1016/j.biopsych.2021.11.025 · 2022 · External reference
Baicalein alleviates depression-like behavior in rotenone-induced Parkinson’s disease model in mice through activating the BDNF/TrkB/CREB pathway
10.1016/j.biopha.2021.111556 · 2021 · External reference
Autism and depression are connected: a report of two complimentary network studies
10.1177/1362361319872373 · 2020 · External reference
Polygonatum sibiricum polysaccharide prevents depression-like behaviors by reducing oxidative stress, inflammation, and cellular and synaptic damage
10.1016/j.jep.2021.114164 · 2021 · External reference
Neuroinflammation in Parkinson’s disease: a target for neuroprotection?
10.1016/s1474-4422(09)70062-6 · 2009 · External reference
Nrf2-dependent persistent oxidative stress results in stress-induced vulnerability to depression
10.1038/mp.2016.144 · 2017 · External reference
Role of Nrf2 in synaptic plasticity and memory in Alzheimer’s disease
10.3390/cells10081884 · 2021 · External reference
Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease
10.1111/acel.13031 · 2019 · External reference
Molecular pathways of major depressive disorder converge on the synapse
10.1038/s41380-022-01806-1 · 2023 · External reference
The synapse as a treatment avenue for Alzheimer’s Disease
10.1038/s41380-022-01565-z · 2022 · External reference
Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson’s disease
10.1016/j.tins.2018.11.001 · 2019 · External reference
Skeletal and neurological risks demonstrated in zebrafish due to second-hand cigarette smoke and the neutralization of luteolin
10.1016/j.tice.2023.102259 · 2023 · External reference
Luteolin photo-protects zebrafish from environmental stressor ultraviolet radiation (UVB)
10.1080/15287394.2023.2249944 · 2023 · External reference
MED1/BDNF/TrkB pathway is involved in thalamic hemorrhage-induced pain and depression by regulating microglia
10.1016/j.nbd.2022.105611 · 2022 · External reference
Luteolin-7-O-glucuronide improves depression-like and stress coping behaviors in sleep deprivation stress model by activation of the BDNF signaling
10.3390/nu14163314 · 2022 · External reference
Luteolin modulates neural stem cells fate determination: in vitro study on human neural stem cells, and in vivo study on LPS-induced depression mice model
10.3389/fcell.2021.753279 · 2021 · External reference
Luteolin alleviates depression-like behavior by modulating glycerophospholipid metabolism in the hippocampus and prefrontal cortex of LOD rats
10.1111/cns.14455 · 2024 · External reference
Noise induced depression-like behavior, neuroinflammation and synaptic plasticity impairments: the protective effects of luteolin
10.1007/s11064-022-03683-0 · 2022 · External reference
Potential anxiolytic and antidepressant-like effects of luteolin in a chronic constriction injury rat model of neuropathic pain: role of oxidative stress, neurotrophins, and inflammatory factors
10.1016/j.intimp.2023.110520 · 2023 · External reference
Luteolin reduces fear, anxiety, and depression in rats with post-traumatic stress disorder
10.1080/19768354.2022.2104925 · 2022 · External reference
Luteolin enhances choroid plexus 5-MTHF brain transport to promote hippocampal neurogenesis in LOD rats
10.3389/fphar.2022.826568 · 2022 · External reference
Neuroprotection by luteolin and gallic acid against cobalt chloride-induced behavioural, morphological and neurochemical alterations in Wistar rats
10.1016/j.neuro.2019.07.005 · 2019 · External reference
Luteolin shows an antidepressant-like effect via suppressing endoplasmic reticulum stress
10.1248/bpb.34.1481 · 2011 · External reference
Luteolin ameliorates depression-like behaviors by suppressing ER stress in a mouse model of Alzheimer’s disease
10.1016/j.bbrc.2021.12.074 · 2022 · External reference
The ethanolic extract of peanut shell attenuates the depressive-like behaviors of mice through modulation of inflammation and gut microbiota
10.1016/j.foodres.2023.112765 · 2023 · External reference
Inflamed astrocytes: a path to depression led by menin
10.1016/j.neuron.2018.10.039 · 2018 · External reference
The protective effect of luteolin on the depression-related dry eye disorder through Sirt1/NF-κB/NLRP3 pathway
10.18632/aging.204479 · 2023 · External reference
Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma
10.1002/biof.1687 · 2021 · External reference
Brain “fog”, inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin
10.3389/fnins.2015.00225 · 2015 · External reference
Luteolin alleviates cognitive impairment in Alzheimer’s disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation
10.1038/s41401-021-00702-8 · 2022 · External reference
Deciphering the potential neuroprotective effects of luteolin against Aβ1-42-induced Alzheimer’s disease
10.3390/ijms22179583 · 2021 · External reference
Looking for a treatment for the early stage of Alzheimer’s disease: preclinical evidence with co-ultramicronized palmitoylethanolamide and luteolin
10.3390/ijms21113802 · 2020 · External reference
Novel luteolin-loaded chitosan decorated nanoparticles for brain-targeting delivery in a sporadic Alzheimer’s disease mouse model: focus on antioxidant, anti-inflammatory, and amyloidogenic pathways
10.3390/pharmaceutics14051003 · 2022 · External reference
Protective effects of luteolin against amyloid beta-induced oxidative stress and mitochondrial impairments through peroxisome proliferator-activated receptor γ-dependent mechanism in Alzheimer’s disease
10.1016/j.redox.2023.102848 · 2023 · External reference
The combination of luteolin and l-theanine improved Alzheimer disease-like symptoms by potentiating hippocampal insulin signaling and decreasing neuroinflammation and norepinephrine degradation in amyloid-β-infused rats
10.1016/j.nutres.2018.09.010 · 2018 · External reference
Luteolin and exercise combination therapy ameliorates amyloid-β1-42 oligomers-induced cognitive impairment in AD mice by mediating neuroinflammation and autophagy
10.3233/jad-220904 · 2023 · External reference
Ameliorating effect of luteolin on memory impairment in an Alzheimer’s disease model
10.3892/mmr.2016.5052 · 2016 · External reference
Luteolin reduces Alzheimer’s disease pathologies induced by traumatic brain injury
10.3390/ijms15010895 · 2014 · External reference
Luteolin inhibits fibrillary β-amyloid1-40-induced inflammation in a human blood-brain barrier model by suppressing the p38 MAPK-mediated NF-κB signaling pathways
10.3390/molecules22030334 · 2017 · External reference
Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats
10.1016/j.pbb.2014.09.005 · 2014 · External reference
Luteolin protects against high fat diet-induced cognitive deficits in obesity mice
10.1016/j.bbr.2014.02.040 · 2014 · External reference
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
10.1038/s41583-019-0240-3 · 2020 · External reference
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
10.1186/s13024-020-00391-7 · 2020 · External reference
Role of genes and treatments for Parkinson’s disease
10.2174/1874196702008010047 · 2020 · External reference
A drosophila model of Parkinson’s disease
10.1038/35006074 · 2000 · External reference
Suppressing Cdk5 activity by luteolin inhibits MPP+-induced apoptotic of neuroblastoma through Erk/Drp1 and Fak/Akt/GSK3β pathways
10.3390/molecules26051307 · 2021 · External reference
Luteolin protects against 6-hydoroxydopamine-induced cell death via an upregulation of HRD1 and SEL1L
10.1007/s11064-023-04019-2 · 2024 · External reference
The association of plmitoylethanolamide with luteolin decreases neuroinflammation and stimulates autophagy in Parkinson’s disease model
10.2174/1871527314666150821102823 · 2015 · External reference
Luteolin protects microglia against rotenone-induced toxicity in a hormetic manner through targeting oxidative stress response, genes associated with Parkinson's disease and inflammatory pathways
10.1080/01480545.2018.1504961 · 2020 · External reference
Luteolin-7-O-glucoside protects dopaminergic neurons by activating estrogen-receptor-mediated signaling pathway in MPTP-induced mice
10.1016/j.tox.2019.152256 · 2019 · External reference
Neuroprotective effects of luteolin against apoptosis induced by 6-hydroxydopamine on rat pheochromocytoma PC12 cells
10.3109/13880209.2012.716852 · 2013 · External reference
Luteolin modulates 6-hydroxydopamine-induced transcriptional changes of stress response pathways in PC12 cells
10.1371/journal.pone.0097880 · 2014 · External reference
Inhibition of α-synuclein contributes to the ameliorative effects of dietary flavonoids luteolin on arsenite-induced apoptotic cell death in the dopaminergic PC12 cells
10.1080/15376516.2017.1339155 · 2017 · External reference
Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation
10.1016/j.neulet.2008.10.046 · 2008 · External reference
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model
10.1016/j.freeradbiomed.2013.01.003 · 2013 · External reference
Synuclein activates microglia in a model of Parkinson’s disease
10.1016/j.neurobiolaging.2007.04.006 · 2008 · External reference
Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson’s disease
10.1096/fj.04-2751com · 2005 · External reference
Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant
10.1371/journal.pone.0162717 · 2016 · External reference
Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype
10.1186/1742-2094-7-3 · 2010 · External reference
Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target
10.1134/s0006297913010033 · 2013 · External reference
10.1023/a:1009229429250 · 2000 · Admitted local publication
Mode of peroxisome proliferator-activated receptor γ activation by luteolin
10.1124/mol.111.076216 · 2012 · External reference
Discovery and characterization of natural product luteolin as an effective inhibitor of human pyridoxal kinase
10.1016/j.bioorg.2023.107057 · 2024 · External reference
Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight
10.1021/bi300531c · 2012 · External reference
Luteolin induces GPX4-dependent ferroptosis and enhances immune activation in colon cancer
10.1016/j.phymed.2025.157117 · 2025 · External reference
Luteolin inhibits ferroptosis of HUVEC by regulating the Sirt1/Nrf2 pathway
10.1007/s12013-025-01831-1 · 2025 · External reference
Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3β enzymatic activity by lowering the interaction energy within the binding cavity
10.1089/jmf.2010.0310 · 2011 · External reference
In silico anti-alzheimer study of phytochemicals from Lamiaceae family through GSK3-β inhibition
10.1038/s41598-023-47069-w · 2024 · External reference
Luteolin protects human ARPE-19 retinal pigment epithelium cells from blue light-induced phototoxicity through activation of Nrf2/Keap1 signaling
10.1080/10715762.2025.2503832 · 2025 · External reference
Luteolin rescues myelin integrity and cognitive-motor function via Nrf2 pathway activation: a natural candidate vs. dimethyl fumarate in cuprizone-induced multiple sclerosis
2025 · External reference
Bioactive flavonoids and catechols as Hif1 and Nrf2 protein stabilizers - Implications for Parkinson’s disease
10.14336/ad.2016.0505 · 2016 · External reference
Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway
2007 · External reference
Luteolin target HSPB1 regulates endothelial cell ferroptosis to protect against radiation vascular injury
10.1371/journal.pone.0311922 · 2024 · External reference
The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells
10.1111/j.1365-2567.2005.02156.x · 2005 · External reference
Active components from Lagotis brachystachya maintain uric acid homeostasis by inhibiting renal TLR4-NLRP3 signaling in hyperuricemic mice
10.1007/s10787-021-00844-5 · 2021 · External reference
Luteolin in the Qi Bi Anshen decoction improves propionic acid-induced autism-like behavior in rats by inhibiting LRP1/MMP9
10.1016/j.phymed.2023.154965 · 2023 · External reference
Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington’s disease mouse striatal cells
10.1016/j.neuint.2015.10.004 · 2015 · External reference
Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies
2019 · External reference
Presence of tau pathology within foetal neural allografts in patients with Huntington’s and Parkinson’s disease
10.1093/brain/awx255 · 2017 · External reference
Differential role of CSF α-synuclein species, tau, and Aβ42 in Parkinson’s disease
10.3389/fnagi.2014.00053 · 2014 · External reference
Tau pathology in Parkinson’s disease
10.3389/fneur.2018.00809 · 2018 · External reference
Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease
10.1093/brain/awac171 · 2022 · External reference
Production of luteolin/biopolymer microspheres by supercritical assisted atomization
10.1021/acs.iecr.7b00211 · 2017 · External reference
Solubility of luteolin in ethanol + water mixed solvents at different temperatures
10.1021/je900381r · 2010 · External reference
Dietary luteolin: a narrative review focusing on its pharmacokinetic properties and effects on glycolipid metabolism
10.1021/acs.jafc.0c08085 · 2021 · External reference
Luteolin as a dietary flavonoid for brain health: modulating neuroinflammation and cognitive decline in neurodegenerative disorders
10.3389/fnut.2026.1774416 · 2026 · External reference
Flavonoids in neurodegeneration: limitations and strategies to cross CNS barriers
10.2174/0929867323666160809094934 · 2016 · External reference
A novel host-guest complex based on biotin functionalized polyamine-β-cyclodextrin for tumor targeted delivery of luteolin
10.1016/j.molstruc.2021.130339 · 2021 · External reference
Brain targeted luteolin-graphene oxide nanoparticle abrogates polyethylene terephthalate induced altered neurological response in zebrafish
10.1007/s11033-023-08960-x · 2023 · External reference
Bioavailability and pharmaco-therapeutic potential of luteolin in overcoming Alzheimer’s disease
10.2174/1871527318666190319141835 · 2019 · External reference
Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters
10.1016/j.biopha.2022.114078 · 2023 · External reference
